Share This Page
Suppliers and packagers for galzin
✉ Email this page to a colleague
galzin
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Eton | GALZIN | zinc acetate | CAPSULE;ORAL | 020458 | NDA | Teva Pharmaceuticals USA, Inc. | 57844-208-52 | 250 CAPSULE in 1 BOTTLE (57844-208-52) | 1997-03-03 |
| Eton | GALZIN | zinc acetate | CAPSULE;ORAL | 020458 | NDA | Teva Pharmaceuticals USA, Inc. | 57844-215-52 | 250 CAPSULE in 1 BOTTLE (57844-215-52) | 1997-03-03 |
| Eton | GALZIN | zinc acetate | CAPSULE;ORAL | 020458 | NDA | Eton Pharmaceuticals, Inc. | 71863-124-25 | 250 CAPSULE, GELATIN COATED in 1 BOTTLE (71863-124-25) | 2025-03-03 |
| Eton | GALZIN | zinc acetate | CAPSULE;ORAL | 020458 | NDA | Eton Pharmaceuticals, Inc. | 71863-125-25 | 250 CAPSULE, GELATIN COATED in 1 BOTTLE (71863-125-25) | 2025-03-03 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Galzin
Introduction
Galzin is a pharmaceutical drug primarily known as a treatment for parasitic infections, notably giardiasis and amoebiasis. Its active ingredient is tinidazole, a 5-nitroimidazole compound with antimicrobial and antiprotozoal properties. The demand for Galzin, especially in regions with high prevalence of parasitic diseases, has driven a global supply chain involving multiple pharmaceutical manufacturers and distributors. Understanding the landscape of suppliers for Galzin is critical for stakeholders involved in procurement, distribution, or competitive analysis in the pharmaceutical sector.
Overview of Galzin and Its Market
Galzin, marketed under various brand names worldwide, is a prescription medication widely used due to its efficacy, favorable safety profile, and ease of administration. The drug's primary formulation encompasses 600 mg tinidazole tablets, with some formulations adapted to local regulatory standards.
The global market for tinidazole and brands like Galzin is fragmented, comprising patented products, generic equivalents, and multiple regional suppliers. The increasing prevalence of parasitic infections in tropical and subtropical climates sustains a steady demand, influencing suppliers' dynamics. Supply chain robustness depends on manufacturing capacities, regulatory approvals, and regional distribution networks.
Major Suppliers and Manufacturers of Galzin
1. Macter Pharmaceutical Co., Ltd. (China)
A significant player in the production of tinidazole, Macter Pharmaceutical supplies bulk active pharmaceutical ingredients (APIs) and finished formulations. The company produces high-quality tinidazole API, which is used by several generic and brand-name manufacturers globally.
2. Jiangsu Hengrui Medicine Co., Ltd. (China)
Hengrui is among leading Chinese pharmaceutical firms manufacturing tinidazole and related nitroimidazoles. Their API manufacturing capabilities encompass high purity standards compliant with global regulatory bodies including the FDA and EMA.
3. Wuxi Hanlin Medical & Biotechnology Co., Ltd. (China)
Known for API manufacturing, Wuxi Hanlin supplies tinidazole API to global markets, including to companies producing Galzin or similar formulations under licensing agreements.
4. Industry-specific Contract Manufacturing Organizations (CMOs)
Numerous CMOs in India, China, and Europe produce finished formulations of tinidazole, including Galzin, under contract for various pharmaceutical companies. Notable firms include:
- Baxter BioPharma Solutions (India)
- Cipla Ltd. (India) — Produces generic antiparasitic medications, including tinidazole formulations.
- Mundipharma (Europe) — Engages in regional distribution and manufacturing.
5. Regional Distributors and Suppliers
In emerging markets, local pharmaceutical distributors often source Galzin from regional manufacturing hubs, sometimes importing APIs or finished formulations from China and India.
Regulatory and Certification Aspects Impacting Suppliers
Suppliers must meet stringent regulatory standards:
- WHO GMP Certification: As many suppliers cater to global markets, compliance with World Health Organization Good Manufacturing Practices (GMP) is critical.
- US FDA and EMA Approvals: A smaller subset of manufacturers have obtained these approvals, enabling direct export to highly regulated markets.
- Regional Regulatory Approvals: Countries like India, China, Brazil, and African nations may accept regional certifications, influencing supply chain choices.
Distribution Channels and Supply Chain Considerations
The supply chain for Galzin often involves:
- API Manufacturers: Producing high-purity tinidazole, these companies supply batch volumes to finished dose formulators.
- Finished Dose Formulators: Enterprises that assemble, package, and label Galzin under licensed agreements.
- Distribution and Logistics: Regional distributors manage warehousing, regulatory compliance, and last-mile delivery, with particular focus on affordability and supply stability.
Challenges and Risks in the Galzin Supply Chain
- Regulatory Variability: Divergent approval requirements can delay market access.
- Quality Assurance: Maintaining quality standards across suppliers is crucial for efficacy and safety.
- Supply Disruptions: Geopolitical issues, manufacturing shortages, or regulatory crackdowns can cause shortages.
- Pricing Pressures: Competition among generic suppliers drives prices downward, impacting margins.
Emerging Trends and Future Outlook
- Generic Expansion: Increasing generic manufacturing capacity is expected to stabilize supplies and lower costs.
- Regional Manufacturing Growth: Focus on regional API production, notably in Africa and Latin America, enhances supply resilience.
- Regulatory Harmonization: Ongoing efforts to standardize GMP and registration processes will streamline supplier approval.
- Biotech Alternatives: While no direct biotech replacements exist for tinidazole, new antiparasitic agents could influence future supply patterns.
Conclusion
The procurement landscape for Galzin hinges on a handful of reputable API manufacturers, primarily in China and India, who supply both finished formulations and APIs globally. Companies sourcing Galzin must prioritize regulatory compliance, quality assurance, and supply chain resiliency. As the demand for antiparasitic medications continues, so will the importance of diversified, compliant suppliers capable of meeting regional needs efficiently.
Key Takeaways
- The primary suppliers for Galzin are API producers in China (e.g., Macter, Hengrui) and India (e.g., Cipla, regional CMOs).
- Ensuring regulatory compliance and quality standards is essential for market access and patient safety.
- Demand for regional manufacturing capacity is expected to grow, particularly in emerging markets.
- Supply chain risks include geopolitical factors, regulatory delays, and quality fluctuations, emphasizing the need for diversified sourcing.
- Emerging trends point toward increased generic competition and regional manufacturing, likely stabilizing prices and supply.
FAQs
Q1: Who are the leading global manufacturers of tinidazole API used in Galzin?
A1: Major manufacturers include Macter Pharmaceutical and Jiangsu Hengrui Medicine in China, alongside Indian companies like Cipla and regional CMOs.
Q2: What regulatory standards must suppliers meet to export Galzin internationally?
A2: Compliance with WHO GMP, and when applicable, FDA and EMA approvals, are essential. Regional certifications are also important depending on destination markets.
Q3: How does regional manufacturing influence the supply stability of Galzin?
A3: Regional manufacturing reduces reliance on global supply chains, mitigates geopolitical risks, and improves availability in local markets.
Q4: What are the primary risks associated with the Galzin supply chain?
A4: Regulatory delays, quality compliance issues, manufacturing disruptions, and geopolitical tensions pose significant risks.
Q5: How might emerging market demand influence future suppliers for Galzin?
A5: Growing demand in Africa, Latin America, and Southeast Asia is likely to encourage regional API production, diversifying and expanding the supplier base.
Sources
- World Health Organization. “Guidelines for the Production of Quality-Assured Medicines.” WHO, 2021.
- U.S. Food and Drug Administration. “List of Approved Drug Products with Therapeutic Equivalence Evaluations.”
- Global Data. “Pharmaceutical Market Analysis.” 2022.
- Company Websites: Macter Pharmaceutical, Jiangsu Hengrui Medicine, Cipla.
- Industry Reports: IQVIA, Healthcare Market Research Reports.
More… ↓
